Aligos Therapeutics Inc (ALGS) - Total Liabilities
Based on the latest financial reports, Aligos Therapeutics Inc (ALGS) has total liabilities worth $32.77 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Aligos Therapeutics Inc to track the company's year-over-year net asset growth rate.
Aligos Therapeutics Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Aligos Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Aligos Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Aligos Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Daebo Magnetic Co.Ltd
KQ:290670
|
Korea | ₩29.68 Billion |
|
Hamelin Gold Ltd
AU:HMG
|
Australia | AU$458.38K |
|
Local Bounti Corp
NYSE:LOCL
|
USA | $592.19 Million |
|
Inventec Besta Co Ltd
TW:8201
|
Taiwan | NT$176.56 Million |
|
Compugates Holdings Bhd
KLSE:5037
|
Malaysia | RM73.01 Million |
|
Sungwoo Electronics Co. Ltd
KQ:081580
|
Korea | ₩47.34 Billion |
|
Barinthus Biotherapeutics plc
NASDAQ:BRNS
|
USA | $24.64 Million |
|
aXichem AB
ST:AXIC-A
|
Sweden | Skr9.69 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Aligos Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Aligos Therapeutics Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aligos Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aligos Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Aligos Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $34.99 Million | -64.68% |
| 2024-12-31 | $99.07 Million | +66.65% |
| 2023-12-31 | $59.45 Million | +38.92% |
| 2022-12-31 | $42.79 Million | -15.49% |
| 2021-12-31 | $50.64 Million | +11.88% |
| 2020-12-31 | $45.26 Million | -78.59% |
| 2019-12-31 | $211.41 Million | +74.03% |
| 2018-12-31 | $121.48 Million | -- |
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifosc… Read more